Abstract
Following treatment for urothelial carcinoma of the bladder (UCB), patients are at risk for urothelial recurrence in the bladder, urethra and upper tracts. This may be due to a field effect in the urothelium or implantation of malignant cells shed from the primary tumor [1]. Conversely, following treatment for upper tract urothelial carcinomas (UTUC) there is a 13-54 % and 6 % risk of recurrence in the bladder and contralateral upper tract, respectively [2]. Theoretical causes for intravesical recurrence following treatment for UTUC include tumor cell shedding during surgery, angiogenic factors released into the bladder as a consequence of the bladder incision, and a compromised immune status due to surgery [3]. Because there is a risk of UTUC after treatment for UCB, and UCB after treatment for UTUC, long-term surveillance of the urothelium is necessary in patients with a history of urothelial carcinoma.
Original language | English |
---|---|
Title of host publication | Upper Urinary Tract Urothelial Carcinoma |
Publisher | Springer International Publishing |
Pages | 91-107 |
Number of pages | 17 |
ISBN (Electronic) | 9783319138695 |
ISBN (Print) | 9783319138688 |
DOIs | |
State | Published - 1 Jan 2015 |
Externally published | Yes |